TITLE

Fighting Fire with Fire: Rekindling the Bevacizumab Debate

AUTHOR(S)
Montero, Alberto J.; Vogel, Charles
PUB. DATE
January 2012
SOURCE
New England Journal of Medicine;1/26/2012, Vol. 366 Issue 4, p374
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the controversy concerning the decision of the U.S. Food and Drug Administration (FDA) to revoke bevacizumab approval in 2012. It says that the agency opposed the use of the substance when combined with paclitaxel to treat patients with metastatic breast cancer. According to the author, the initial approval by the FDA was only based on the improvement in progression-free survival.
ACCESSION #
70605293

 

Related Articles

  • Bevacizumab plus paclitaxel granted accelerated approval for breast cancer. Lawrence, Leah; Adams, Stacey L. // Hem/Onc Today;3/10/2008, Vol. 9 Issue 4, p1 

    The article reports on the U.S. Food & Drug Administration accelerated approval granted to bevacizumab in combination with paclitaxel for the treatment of metastatic breast cancer. The approval of the drug was based on findings from the E2100, an international, multi-center, randomized,...

  • Changing End Points in Breast-Cancer Drug Approval � The Avastin Story. D'Agostino, Ralph B. // New England Journal of Medicine;7/14/2011, Vol. 365 Issue 2, pN.PAG 

    The author discusses the proposal to consider progression-free survival rather than overall survival as the primary end point for breast cancer studies. He cites the case of Genentech's Avastin (bevacizumab) for use in combination with paclitaxel for the treatment of human epidermal growth...

  • FDA Actions. Elliott, William T. // Primary Care Reports;Apr2008, Vol. 14 Issue 4, p2 

    The article announces the U.S. Food and Drug Administration (FDA) approval of bevacizumab (Avastin) for the treatment of metastatic HER2-negative breast cancer when used in combination with paclitaxel reducing disease progression compared to treatment with paclitaxel alone. The article also...

  • Genentech's combination therapy receives FDA's accelerated approval.  // PharmaWatch: Biotechnology;Apr2008, Vol. 7 Issue 4, p11 

    The article reports that Genentech Inc., a biotechnology group, has received an accelerated approval from the U.S. Food and Drug Administration (FDA) for its drug Avastin, a paclitaxel chemotherapy-combined treatment for patients with metastatic HER2-negative breast cancer. It was stated that...

  • Bevacizumab in Metastatic Breast Cancer: Ready for Prime Time? Mandock, Katherine; Soefje, Scott A.; Adams, R. // Journal of Hematology Oncology Pharmacy;Dec2011, Vol. 1 Issue 4, p6 

    The article focuses on the U.S. Food and Drug Administration's (FDA) decision to remove bevacizumab's current labeled indication for metastatic breast cancer (MBC). Postapproval trials required with the FDA approval for bevacizumab for treatment did not demonstrate an overall survival (OS)...

  • Avastin disappoints against ovarian cancer.  // Business Journal Serving Fresno & the Central San Joaquin Valley;12/30/2011, Issue 324433, p3 

    The article focuses on recent studies conducted by the U.S. Food and Drug Administration (FDA) in which it found that avastin drug is incapable of treating breast cancer and ovarian cancer.

  • FDA revokes approval of bevacizumab for patients with metastatic breast cancer. Harris, Jason; Levine, Ellis // Hem/Onc Today;12/10/2011, Vol. 12 Issue 23, p1 

    The article reports on the revocation of the approval of bevacizumab for patients with metastatic breast cancer by the U.S. Food and Drug Administration (FDA).

  • Pharmacovigilance & Regulatory News.  // Reactions Weekly;11/26/2011, Issue 1379, p2 

    The article reports on the withdrawal of the U.S. Food and Drug Administration's approval of the breast cancer indication for bevacizumab in November 2011.

  • FDA Panel Votes Against Avastin Use For Breast Cancer Patients. Young, Donna // BioWorld Today;12/6/2007, Vol. 18 Issue 236, p1 

    The article deals with the pending approval by the U.S. Food and Drug Administration (FDA) of Genentech's Avastin in combination with the chemotherapy agent paclitaxel as a treatment for metastatic breast cancer. Richard Pazdur of the FDA said that the agency would consider the overall...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics